+

EP1265634A4 - Procede et composition pour traiter une hyperreactivite bronchique - Google Patents

Procede et composition pour traiter une hyperreactivite bronchique

Info

Publication number
EP1265634A4
EP1265634A4 EP01918368A EP01918368A EP1265634A4 EP 1265634 A4 EP1265634 A4 EP 1265634A4 EP 01918368 A EP01918368 A EP 01918368A EP 01918368 A EP01918368 A EP 01918368A EP 1265634 A4 EP1265634 A4 EP 1265634A4
Authority
EP
European Patent Office
Prior art keywords
composition
airway hyperresponsiveness
treating airway
treating
hyperresponsiveness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01918368A
Other languages
German (de)
English (en)
Other versions
EP1265634A1 (fr
Inventor
Erwin W Gelfand
Mika Maekela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Jewish Health
Original Assignee
National Jewish Medical and Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Jewish Medical and Research Center filed Critical National Jewish Medical and Research Center
Publication of EP1265634A1 publication Critical patent/EP1265634A1/fr
Publication of EP1265634A4 publication Critical patent/EP1265634A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5428IL-10
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01918368A 2000-03-14 2001-03-06 Procede et composition pour traiter une hyperreactivite bronchique Withdrawn EP1265634A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52504300A 2000-03-14 2000-03-14
US525043 2000-03-14
PCT/US2001/007069 WO2001068130A1 (fr) 2000-03-14 2001-03-06 Procede et composition pour traiter une hyperreactivite bronchique

Publications (2)

Publication Number Publication Date
EP1265634A1 EP1265634A1 (fr) 2002-12-18
EP1265634A4 true EP1265634A4 (fr) 2005-12-28

Family

ID=24091672

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01918368A Withdrawn EP1265634A4 (fr) 2000-03-14 2001-03-06 Procede et composition pour traiter une hyperreactivite bronchique

Country Status (4)

Country Link
EP (1) EP1265634A4 (fr)
AU (2) AU4545301A (fr)
CA (1) CA2403196A1 (fr)
WO (1) WO2001068130A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031532A1 (fr) * 1996-02-28 1997-09-04 University Of Medicine & Dentistry Of New Jersey Interleukine-10 anti-sens et procedes d'utilisation
WO1998010787A2 (fr) * 1996-09-11 1998-03-19 Prendergast Patrick T Therapie a but immunitaire
US5843697A (en) * 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
WO1999027937A2 (fr) * 1997-11-26 1999-06-10 Previsan Ag Procede d'inhibition de la production cellulaire de cytokines
WO2000071140A2 (fr) * 1999-05-21 2000-11-30 Foodscience Corporation Procedes et compositions de modulation de la reponse immunitaire et de traitement des maladies inflammatoires

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
WO1997026278A1 (fr) * 1996-01-18 1997-07-24 Steeno Research Group A/S Analogues synthetiques d'il-10

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031532A1 (fr) * 1996-02-28 1997-09-04 University Of Medicine & Dentistry Of New Jersey Interleukine-10 anti-sens et procedes d'utilisation
US5843697A (en) * 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
WO1998010787A2 (fr) * 1996-09-11 1998-03-19 Prendergast Patrick T Therapie a but immunitaire
WO1999027937A2 (fr) * 1997-11-26 1999-06-10 Previsan Ag Procede d'inhibition de la production cellulaire de cytokines
WO2000071140A2 (fr) * 1999-05-21 2000-11-30 Foodscience Corporation Procedes et compositions de modulation de la reponse immunitaire et de traitement des maladies inflammatoires

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARIMA H ET AL: "DESIGN OF POTENT PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDES DIRECTED TO HUMAN INTERLEUKIN 10 GENE PRODUCT AND THEIR EVALUATION OF ANTISENSE ACTIVITY IN U937 CELLS", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 16, no. 8, August 1999 (1999-08-01), pages 1163 - 1171, XP001053078, ISSN: 0724-8741 *
ARIMA H ET AL: "SPECIFIC INHIBITION OF INTERLEUKIN-10 PRODUCTION IN MURINE MACROPHAGE-LIKE CELLS BY PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDES", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 8, August 1998 (1998-08-01), pages 319 - 327, XP002926349, ISSN: 1087-2906 *
GREENBERGER MARC J ET AL: "Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia.", JOURNAL OF IMMUNOLOGY, vol. 155, no. 2, 1995, pages 722 - 729, XP002236220, ISSN: 0022-1767 *
KONZO K R ET AL: "Inhibition of interleukin-10 (IL-10) production by fluticasone (Flu).", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 95, no. 1 PART 2, 1995, Fifty-first Annual Meeting of the American Academy of Allergy and Immunology;New York, New York, USA; February 24-March 1, 1995, pages 300, XP008015571, ISSN: 0091-6749 *
LU L J ET AL: "Inhibition of interleukin-10 (IL-10) production by interleukin-8 (IL-8).", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 95, no. 1 PART 2, 1995, Fifty-first Annual Meeting of the American Academy of Allergy and Immunology;New York, New York, USA; February 24-March 1, 1995, pages 345, XP008015572, ISSN: 0091-6749 *
See also references of WO0168130A1 *

Also Published As

Publication number Publication date
AU4545301A (en) 2001-09-24
EP1265634A1 (fr) 2002-12-18
AU2001245453B2 (en) 2005-08-25
CA2403196A1 (fr) 2001-09-20
WO2001068130A1 (fr) 2001-09-20

Similar Documents

Publication Publication Date Title
AU2002219945A1 (en) Composition and method for treating snoring
AU1484202A (en) Method for treating films
IL132133A0 (en) Method and composition for treating sleep apnea
AU2001243654A1 (en) System and method for treating process material
GB0008264D0 (en) Novel method and compounds
AU6832101A (en) Composition and method
AU4163402A (en) Composition and method
PL353136A1 (en) Method for treating architectural material
EP1351647A4 (fr) Compositions et methodes pour traiter l'hyperpigmentation
HU0001629D0 (en) Method for treating plants and compositions for it
EP1363761A4 (fr) Materiau et procede de traitement pour bois debite
HUP0204089A3 (en) Method and composition for treating resistance to antihypertensives and related conditions
IL161073A0 (en) Composition and method for treating diabetes
SG103300A1 (en) Method and apparatuses for electrochemically treating an article
IL149367A0 (en) Method and compositions for treating pulmonary diseases
AU4904200A (en) Method and system for treating swine manure
HK1046853A1 (zh) 治療肝癌的方法及組成物
GB0118883D0 (en) Method for treating objects
GB0123898D0 (en) Method for treating objects
GB0122810D0 (en) Method for treating objects
GB0123897D0 (en) Method for treating objects
GB0112921D0 (en) Control apparatus and method
AU4545301A (en) Method and composition for treating airway hyperresponsiveness
GB0006867D0 (en) Method and composition for skin lightening
AU2001245453A1 (en) Method and composition for treating airway hyperresponsiveness

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021007

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/20 B

Ipc: 7A 61K 39/395 A

Ipc: 7C 07K 16/00 B

Ipc: 7C 12P 19/34 B

A4 Supplementary search report drawn up and despatched

Effective date: 20051115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080916

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载